FORT WASHINGTON, Pa. — Many consumers don’t heed safety factors when choosing and using over-the-counter pain relievers, a national survey supported by McNeil Consumer Healthcare finds. Of 1,292 U.S. adults who have used an OTC pain reliever in the last 90 days, 65% don’t consider other OTC medicines they are taking and 45% don’t take
COLORADO SPRINGS, Colo. — As consumers with diabetes take more control over their care, food and pharmacy retailers are being challenged to come up with solutions to meet their needs, according to research from the Global Market Development Center (GMDC). GMDC’s latest Health & Wellness Best Practices report, titled “Retail Partnering to Serve the Shopper
NEW BRUNSWICK, N.J. — Health care giant Johnson & Johnson is sharpening its aim at the growing diabetes epidemic. J&J said this week that it plans to debut the Diabetes Collaboration Zone, a cross-enterprise display of diabetes-focused products, solutions and resources, at the 2016 National Association of Chain Drug Stores Total Store Expo, which runs
WESTPORT, Conn. — The venerable Mylanta antacid and anti-gas liquid has been brought back to store shelves nationwide by Infirst Healthcare USA, a subsidiary of United Kingdom-based Infirst Healthcare Ltd. Infirst said Tuesday that the “new” Mylanta features an improved taste, extra coating power and new products. The original product, made by Johnson & Johnson’s
NEW BRUNSWICK, N.J. — Johnson & Johnson Consumer Inc. plans to acquire Vogue International, maker of the OGX hair care brand, for about $3.3 billion in cash. Johnson & Johnson said Thursday that the deal includes the OGX line of shampoos, conditioners, treatments, styling products, body care and bath products, as well as the FX
NEW BRUNSWICK, N.J. — Johnson & Johnson has named Alissa Hsu Lynch as worldwide marketing vice president of diabetes care. Lynch had served as vice president of sales strategy, operations and global capabilities at J&J since rejoining the company September 2013. In that post, Lynch led the strategic development of key retail initiatives across J&J’s
DUBLIN, Ohio — Cardinal Health has completed its acquisition of Johnson & Johnson’s Cordis cardiology and endovascular device business for $1.944 billion. Cardinal said Sunday evening that the integration of Cordis off to a strong start, with management teams in place worldwide. The company noted that planning has been ongoing since the deal was announced
Two major drug chain manufacturer partners — Johnson & Johnson and Procter & Gamble — are involved in collaborations that could make a big impact in fighting flu and heart disease. Scientists from The Scripps Research Institute (TSRI) and J&J’s Janssen pharmaceutical subsidiary have found a way to induce antibodies to fight a wide range
NEW BRUNSWICK, N.J. — Johnson & Johnson Consumer Products Inc. (J&J) is now sponsoring the Walgreens Balance Rewards for healthy choices program in order to encourage and reward healthy behavior. Centered on the shared belief that the health and well-being of families everywhere is critically important, both companies are making it easier for customers to
PRINCETON JUNCTION, N.J. — Market Performance Group (MPG) announced that founding partner Tim Toohey is retiring and that the company has named two new members to its advisory board. MPG said Tuesday that Toohey is retiring to pursue other business and personal interests but will continue to contribute his knowledge and consulting expertise as a
DUBLIN, Ohio — Cardinal Health Inc. plans to acquire cardiology and endovascular device maker Cordis from Johnson & Johnson for $1.944 billion. Cardinal said Monday that the cash deal would significantly advance its offering of interventional cardiology and endovascular solutions for integrated health systems and their patients by giving the company immediate global scale in
WASHINGTON — A Food and Drug Administration panel has recommended that the agency approve what could become the country’s first biosimilar. The panel unanimously urged approval of Sandoz’s filgrastin (Neupogen), a cancer treatment. “This encouraging step forward means that it is very likely now only a question of when, rather than if, filgrastin will be available
